Xiidra

Manufactured by Novartis

Sourced in United States

Xiidra is a prescription eye drop medication used to treat the signs and symptoms of dry eye disease. It contains the active ingredient lifitegrast, which works to reduce inflammation in the eyes.

Automatically generated - may contain errors

Lab products found in correlation

Restasis, by Abbvie (2 mentions)

2 protocols using xiidra

Topical Anti-Inflammatory Therapy for Dry Eye

Check if the same lab product or an alternative is used in the 5 most similar protocols

Thirty individuals were prescribed a topical anti-inflammatory therapy, either cyclosporine 0.05% (Restasis, Allergan Inc., Irvine, CA, USA) or lifitegrast 5% (Xiidra, Novartis Pharmaceuticals Corp., East Hanover, NJ, USA) as part of the clinical care. Overall, this group had higher DED symptom severity (DEQ5: 13.97 ± 4.17 vs. 10.94 ± 5.20, p = 0.002) and lower tear production (Schirmer: 10.28 ± 7.16 vs. 13.28 ± 7.33, p = 0.04) compared to individuals not treated with an anti-inflammatory drop. However, the decision to treat was based on the preference of the treating physician. In all patients, a topical corticosteroid was prescribed twice daily for the first month (fluorometholone ophthalmic suspension, 0.1%). The DED symptom response was subjectively assessed approximately 3 months later. Individuals were sorted into two groups: individuals who characterized their ocular surface symptoms as partially or completely resolved upon starting anti-inflammatory therapy, and those with stable or worsening symptoms.

Acuna K., Choudhary A., Locatelli E., Rodriguez D.A., Martin E.R., Levitt R.C, & Galor A. (2023). Impact of Tumor Necrosis Factor Receptor 1 (TNFR1) Polymorphism on Dry Eye Disease. Biomolecules, 13(2), 262.

+ Open protocol

+ Expand

Dry Eye Exclusion Criteria Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

Subjects whose records indicated the use of prohibited medications (topical, topical ophthalmic, systemic and/or injectable) during the appropriate pre–study washout period and/or during the 14-day vehicle run-in period prior to randomization were excluded from efficacy analyses prior to database lock.
Subjects had not received any investigational drug or device within 30 days of screening, nor during the study except per-protocol. Subjects who were on systemic (oral) therapy for the treatment of Sjögren’s Syndrome must have been on stable systemic treatment defined as the same treatment for the immediately prior 90 days. The use of cyclosporin (compounded or Restasis® Allergan, Irvine CA or Cequa, Sun Pharmaceuticals, Mumbai, India) or lifitegrast (Xiidra®, Novartis, Basel, CH) within 14 days prior to the screening examination was prohibited. Subjects did not have alterations to (insertion or removal) punctal plugs in the study eye, within 14 days prior to the screening examination and during the entire study.
Medications, topical or systemic, known to exacerbate dry eye were prohibited during the study.

Tauber J., Laurie G.W., Parsons E.C, & Odrich M.G. (2022). Lacripep for the Treatment of Primary Sjögren–Associated Ocular Surface Disease: Results of the First-In-Human Study. Cornea, 42(7), 847-857.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!